Prasugrel and Aspirin Tablet
Description
PRASUROOT-AP 10/75
Prasugrel 10 mg and Aspirin 75 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Prasugrel Hydrochloride IP equivalent to Prasugrel — 10 mg
Aspirin IP — 75 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
PRASUROOT-AP 10/75 is a potent dual antiplatelet therapy (DAPT) combination containing Prasugrel 10 mg and Aspirin 75 mg, formulated for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), post-percutaneous coronary intervention (PCI), and coronary artery disease. This combination provides comprehensive platelet inhibition, significantly reducing the risk of myocardial infarction, stent thrombosis, ischemic stroke, and recurrent cardiovascular events.
Prasugrel is a third-generation P2Y12 receptor inhibitor that provides rapid, potent, and consistent platelet inhibition, while Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 synthesis and platelet aggregation. Together, they offer superior protection against arterial thrombosis in high-risk cardiovascular patients.
PRASUROOT-AP 10/75 is particularly beneficial for patients with acute coronary syndrome undergoing PCI, post-coronary stenting, ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), unstable angina, diabetes-associated coronary artery disease, and patients requiring long-term secondary prevention of cardiovascular events.
Technical Knowledge of Prasugrel and Aspirin
Prasugrel is a prodrug that undergoes rapid hepatic activation to form an active metabolite that irreversibly inhibits the platelet P2Y12 ADP receptor. This prevents ADP-mediated activation of the GPIIb/IIIa receptor complex, resulting in potent inhibition of platelet aggregation.
Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) in platelets, inhibiting thromboxane A2 production and suppressing platelet activation for the lifespan of circulating platelets.
The combination of Prasugrel and Aspirin targets two distinct pathways of platelet activation, providing enhanced antithrombotic efficacy and reducing the risk of arterial thrombotic complications.
Mechanism of Action
Prasugrel irreversibly inhibits the platelet P2Y12 receptor, blocks ADP-mediated platelet activation, prevents GPIIb/IIIa activation, and reduces platelet aggregation.
Aspirin irreversibly inhibits COX-1, suppresses thromboxane A2 synthesis, reduces platelet activation, and provides sustained antiplatelet protection.
Key Benefits
Potent dual antiplatelet therapy
Reduces the risk of myocardial infarction
Prevents stent thrombosis
Reduces recurrent ischemic cardiovascular events
Provides rapid and sustained platelet inhibition
Effective in acute coronary syndrome
Supports long-term secondary cardiovascular prevention
Suitable for post-PCI antiplatelet management under medical supervision
Clinical Applications
PRASUROOT-AP 10/75 is commonly prescribed for acute coronary syndrome, post-percutaneous coronary intervention, post-coronary stenting, STEMI, NSTEMI, unstable angina, coronary artery disease, diabetic cardiovascular disease, and secondary prevention of recurrent cardiovascular events.
Facts About Prasugrel and Aspirin
Prasugrel provides more potent and consistent platelet inhibition than several earlier P2Y12 inhibitors and has strong clinical evidence supporting reduction of ischemic events in ACS patients undergoing PCI. Aspirin remains the cornerstone of antiplatelet therapy for cardiovascular disease. Their combination is recommended in major international cardiology guidelines for appropriate patients following acute coronary syndromes and coronary intervention.
Key Facts
Dual antiplatelet therapy (DAPT)
Prasugrel 10 mg for potent P2Y12 inhibition
Aspirin 75 mg for COX-1 inhibition
Reduces stent thrombosis and recurrent ischemic events
Essential therapy after PCI and acute coronary syndrome
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
PRASUROOT-AP 10/75 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, acute coronary syndrome, diabetes, hypertension, and coronary interventions creates strong prescription demand and long-term market potential for this combination.
Why Choose PRASUROOT-AP 10/75 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Prasugrel 10 mg and Aspirin 75 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
PRASUROOT-AP 10/75 from DIABGLYM combines potent dual antiplatelet protection, evidence-based cardiovascular therapy, comprehensive thrombotic risk reduction, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Prasugrel and Aspirin formulation.
